Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial

Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio 44106, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.5). 05/1996; 57(5):184-9.
Source: PubMed


It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past of treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults.
An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale.
Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p < .02 for the ARS; p < .005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects.
Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.

44 Reads
    • "With a maximum recommended dosage of 375 mg, it is prescribed for a range of conditions, including major depression , generalized anxiety, social anxiety, and panic disorder (Bakish, 1999; Silverstone and Ravindran, 1999; Gorman et al., 2000; Thase et al., 2000; Thase et al., 2001; Anderson et al., 2008). Its off-label prescription has been reported as well in fibromyalgia (Sayar et al., 2003), tension-type headache (Zissis et al., 2007), migraine prophylaxis (Ozyalcin et al., 2005), cocaine dependence (McDowell et al., 2000), and a range of other conditions (Findling et al., 1996; Gelenberg et al., 2000; Freeman et al., 2001; Galvez et al., 2004; Rowbotham et al., 2004; Evans et al., 2005; Amsterdam et al., 2010). Venlafaxine is available either as an immediate-release (tablet) or as an extended-release formulation (venlafaxine XR capsule and tablet; Wellington and Perry, 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers' experiences as described in venlafaxine misuse web reports. Methods A literature search was performed using PubMed, Embase, and Medline. Posts/threads relating to venlafaxine misuse issues were identified through Google® and Yahoo® English-language searches. Resulting websites' data were then qualitatively assessed, and information was collected on a range of issues, including dosage, drug intake modalities, untoward drug effects, and association with other recreational drugs. Results A few literature case reports focusing on venlafaxine as a misusing drug were here identified. The molecule was here typically ingested or snorted at dosages up to 10–15 times higher than those clinically advised, obtaining MDMA/amphetamine-like stimulant and psychedelic effects. Polydrug misuse was commonly reported. Venlafaxine appeared to be widely available online for sale. Conclusions Physicians should carefully evaluate patients for history of drug dependence and observe them for signs of venlafaxine misuse.
    Human Psychopharmacology Clinical and Experimental 07/2015; 30(4):255-261. DOI:10.1002/hup.2476 · 2.19 Impact Factor
  • Source
    • "Aufgrund der noradrenergen Modulation gab es Mitte der 90er-Jahre Fallberichte und offene Studien zur Wirksamkeit des Serotonin-und Noradrenalin-Wiederaufnahmehemmers Venlafaxin in der Behandlung von Erwachsenen mit ADHD. Während Findling et al. (1996) "

    Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 01/2009; 37(1):13-25. DOI:10.1024/1422-4917.37.1.13 · 0.99 Impact Factor
  • Source
    • "These included ratings of the effects of cannabis use on six aspects of their lives (see items in Table 2 below) and ratings of 10 aspects of their quality of life (see items in Table 3 below). We also administered two measures of symptoms of childhood attention deficit hyperactivity disorder (ADHD) – the Wender Utah Rating Scale (WURS) (Ward et al. 1993) and the ADHD rating scale (DuPaul, 1991), with the latter instrument modified to include 18 questions covering all of the DSM-IV inattention criteria and hyperactivity-impulsivity criteria (Findling et al. 1996). However, these two instruments were introduced after the study began and were administered to only 109 of the 180 subjects (33 current users, 31 former users and 45 controls). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although cannabis is the most widely used illicit drug in the United States, few recent American studies have examined the attributes of long-term heavy cannabis users. Using a case-control design, we obtained psychological and demographic measures on 108 individuals, age 30-55, who had smoked cannabis a mean of 18000 times and a minimum of 5000 times in their lives. We compared these heavy users to 72 age-matched control subjects who had smoked at least once, but no more than 50 times in their lives. We found no significant differences between the two groups on reported levels of income and education in their families of origin. However, the heavy users themselves reported significantly lower educational attainment (P < 0.001) and income (P = 0.003) than the controls, even after adjustment for a large number of potentially confounding variables. When asked to rate the subjective effects of cannabis on their cognition, memory, career, social life, physical health and mental health, large majorities of heavy users (66-90%) reported a 'negative effect'. On several measures of quality of life, heavy users also reported significantly lower levels of satisfaction than controls. Both objective and self-report measures suggest numerous negative features associated with long-term heavy cannabis use. Thus, it seems important to understand why heavy users continue to smoke regularly for years, despite acknowledging these negative effects. Such an understanding may guide the development of strategies to treat cannabis dependence.
    Psychological Medicine 12/2003; 33(8):1415-22. · 5.94 Impact Factor
Show more

Similar Publications